Benzinga | Mar 4, 2021 07:09AM EST

VYNE Therapeutics Q4 EPS $(0.43) Beats $(0.53) Estimate, Sales $4.29M Miss $4.71M Estimate

VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.53) by 18.87 percent. The company reported quarterly sales of $4.29 million which missed the analyst consensus estimate of $4.71 million by 9.00 percent.